TANGO THERAPEUTICS IN

Tango Therapeutics to Participate in Upcoming Investor Conferences

01 Jun 2023 04:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

09 May 2023 04:00:03 By Nasdaq GlobeNewswire

Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

18 Apr 2023 13:30:00 By Nasdaq GlobeNewswire

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers

03 Apr 2023 04:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights

27 Mar 2023 04:00:01 By Nasdaq GlobeNewswire

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

14 Mar 2023 17:11:45 By Nasdaq GlobeNewswire

Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank

10 Mar 2023 19:15:27 By Nasdaq GlobeNewswire

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Mar 2023 04:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics to Participate in Upcoming Investor Conferences

01 Mar 2023 04:00:01 By Nasdaq GlobeNewswire

Tango Therapeutics to Participate in Upcoming Investor Conferences

02 Feb 2023 04:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates

25 Jan 2023 04:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights

10 Nov 2022 04:00:03 By Nasdaq GlobeNewswire

Tango Therapeutics to Participate in Upcoming Investor Conferences

07 Nov 2022 04:00:01 By Nasdaq GlobeNewswire

Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

19 Oct 2022 04:00:01 By Nasdaq GlobeNewswire

Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting

05 Oct 2022 05:10:00 By Nasdaq GlobeNewswire

Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

06 Sep 2022 04:00:01 By Nasdaq GlobeNewswire

Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights

10 Aug 2022 04:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

02 Aug 2022 04:00:01 By Nasdaq GlobeNewswire

Tango Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes

27 Jun 2022 04:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

08 Jun 2022 04:00:01 By Nasdaq GlobeNewswire